Compare Mesoblast Limited (MESO) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nutrien Ltd — how do they compare? Mesoblast Limited trades at $14.3 (market cap $1.75B), while Nutrien Ltd trades at $67.2 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 19× Mesoblast Limited's market cap, and Nutrien Ltd pays a 3.15% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Nutrien Ltd for 59 Days on average.
| MESO | NTR | |
|---|---|---|
Market Cap | $1.75B | $33.31B |
Volume | 239,027 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $83.94 |
52-Week Low | $13.19 | $53.64 |
Typical Hold Time | 15 Days | 59 Days |
Enterprise Value | $1.83B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Nutrien (NTR) trades at $68.29, down 2.4% today, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation metrics with P/E of 14.14 and P/S of 1.2, while profitability metrics include 8.44% net margin and 9.34% ROE. Recent news highlights industry headwinds from potential Belarus potash imports and an upcoming Investor Day in November 2026.
The outlook remains cautiously optimistic with 60.6% analyst buy ratings and a $76.14 consensus target, though risks include fertilizer price volatility and competitive pressures. Cash flow trends show consistent operational strength but negative net flows in recent years, requiring careful monitoring of debt levels and agricultural market cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
